Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Cancer Discov. 2016 Jul 15;6(9):986–1005. doi: 10.1158/2159-8290.CD-15-1297

Figure 5. HDAC1 as enhancer of oncomiR, miR-21.

Figure 5

(A) Gene track of HDAC1 occupancy at miR-21 promoter in normal donor, CTCL patient and IL-15-stimulated normal donor CD4+ T-cells (↱ = TSS). (B) Relative expression of miR-21 in normal donor and CTCL patient CD4+ T-cells. Mature miR-21 transcript was normalized to RNU43 and the values are presented as mean ± SEM, N=5 for normal donor CD4+ T-cells and N=10 for CTCL patient CD4+ T-cells. On the right side is relative expression of miR-21 in normal donor CD4+ T-cells that were either exposed to PBS (control) or 100ng/ml IL-15 in vitro for 24 hours. CD4+ T cells from four different normal donors were exposed to IL-15 as shown by symbols of different colors. Mature miR-21 transcript was normalized to RNU43 and the values are presented as mean ± SEM, N=3 for each normal donor. (C) Relative expression of miR-21 in normal donor CD4+ T-cells transfected with either ShGFP (control) or ShHDAC1 GFP plasmids. Cells were harvested at 24 hours for expression of mature miR-21 transcript and normalized to RNU43. The values are presented as mean ± SEM, N=3 for each condition. (D) Relative expression of miR-21 in the human CTCL cell line Hut78 cells treated with either DMSO (control) or 150nM Merck60 (an HDAC1/2 inhibitor). Cells were harvested at 24 hours for expression of mature miR-21 transcript and normalized to RNU43. The values are presented as mean ± SEM, N=3 for each condition.